Tasmanians are expected to be able to access a Moderna Covid vaccine manufactured in Australia later this year.

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

An epidemiologist said the Franklin County resolution was "based on conspiracy and misinformation against the COVID-19 ...

The virus does not enter human cells as readily as SARS-CoV-2 does, the Chinese researchers reported in the journal Cell, ...

Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.

The Montana House of Representatives on Wednesday voted overwhelmingly against House Bill 371, a measure that would have banned mRNA vaccines — used primarily in COVID-19 vaccines and booster shots — ...

Norovirus infection rates are extremely high this year, raising the question: Why can’t a vaccine protect us from the stomach ...

Last year, the stock declined 62.6%, significantly underperforming the S&P 500 Index’s ($SPX) gain of 25%. Moderna reported its fourth quarter and full fiscal 2024 results last week. So far this year, ...

Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 - a sharp decline from the $2.8bn recorded in the ...

Persistent levels of spike protein from COVID-19 vaccines could be associated with a range of chronic symptoms like excessive ...